Program
EGFR/HER2 Mutant-selective Inhibitor BH-30643
Also written as “BH-30643” and “BH-30643 combo therapy with Carboplatin/Pemetrexed”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by BlossomHill Therapeutics.
Furthest: phase 2, since Nov 19, 20241 company-led study, 1 open or runningNext primary completion: Jan 31, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BlossomHill Therapeutics | 11 open or running | phase 2since Nov 19, 2024 | Nov 19, 2024 | Jan 31, 2029phase 2 · NCT06706076 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2024First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06706076 · 675 planned · United States, Australia, Canada and more
Ahead
- Jan 31, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06706076
TargetBeta
“An orally bioavailable, mutant-selective, reversible macrocyclic inhibitor of human epidermal growth factor receptor (EGFR) and epidermal growth factor receptor 2 (HER2), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| enozertinibrule | oric-pharmaceuticals | phase 2 | 3 |
| GENSCI139rule | Changchun GeneScience Pharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06706076Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Recruiting | Jan 31, 2029 | 675 |
How it is read
Names in the registry
- “BH-30643”, 2 entries
- “BH-30643 combo therapy with Carboplatin/Pemetrexed”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.